Amydis is developing novel, patent-protected molecules, “ocular tracers”, which enable direct visualization of CNS disease-related molecular changes (biomarkers) in the eye. With this first-in-class capability, Amydis is poised to revolutionize the ability of physicians and researchers to explore the eye for a broad spectrum of diseases, which have to date required long-term clinical evaluation and the use of invasive testing for definitive diagnosis. The company has a discovery platform and proprietary know-how that positions it as first mover and a global leader in developing ocular tracers for human diseases. The future of effective, sustainable healthcare depends on knowledge gained through early diagnostics.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.